1. Home
  2. GSBD vs OCUL Comparison

GSBD vs OCUL Comparison

Compare GSBD & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSBD
  • OCUL
  • Stock Information
  • Founded
  • GSBD 2012
  • OCUL 2006
  • Country
  • GSBD United States
  • OCUL United States
  • Employees
  • GSBD N/A
  • OCUL N/A
  • Industry
  • GSBD Finance: Consumer Services
  • OCUL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSBD Finance
  • OCUL Health Care
  • Exchange
  • GSBD Nasdaq
  • OCUL Nasdaq
  • Market Cap
  • GSBD 1.4B
  • OCUL 1.2B
  • IPO Year
  • GSBD N/A
  • OCUL 2014
  • Fundamental
  • Price
  • GSBD $11.64
  • OCUL $7.33
  • Analyst Decision
  • GSBD Hold
  • OCUL Strong Buy
  • Analyst Count
  • GSBD 2
  • OCUL 9
  • Target Price
  • GSBD $13.00
  • OCUL $16.22
  • AVG Volume (30 Days)
  • GSBD 828.9K
  • OCUL 1.7M
  • Earning Date
  • GSBD 05-06-2025
  • OCUL 03-03-2025
  • Dividend Yield
  • GSBD 16.51%
  • OCUL N/A
  • EPS Growth
  • GSBD N/A
  • OCUL N/A
  • EPS
  • GSBD 0.55
  • OCUL N/A
  • Revenue
  • GSBD $434,374,000.00
  • OCUL $63,723,000.00
  • Revenue This Year
  • GSBD N/A
  • OCUL $14.02
  • Revenue Next Year
  • GSBD N/A
  • OCUL $15.47
  • P/E Ratio
  • GSBD $22.09
  • OCUL N/A
  • Revenue Growth
  • GSBD N/A
  • OCUL 9.03
  • 52 Week Low
  • GSBD $11.39
  • OCUL $4.06
  • 52 Week High
  • GSBD $15.94
  • OCUL $11.78
  • Technical
  • Relative Strength Index (RSI)
  • GSBD 30.84
  • OCUL 46.20
  • Support Level
  • GSBD $12.14
  • OCUL $7.36
  • Resistance Level
  • GSBD $12.38
  • OCUL $8.04
  • Average True Range (ATR)
  • GSBD 0.20
  • OCUL 0.45
  • MACD
  • GSBD -0.02
  • OCUL -0.01
  • Stochastic Oscillator
  • GSBD 24.04
  • OCUL 16.75

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

About OCUL Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Share on Social Networks: